Found in the ISIS website...Drugs in Development.ATL1102ATL1102...

Found in the ISIS website...Drugs in Development.


ATL1102

ATL1102 is an antisense inhibitor of CD49d, which is a subunit of Very Late Antigen-4, or VLA-4. Studies in animal models have demonstrated that inhibiting VLA-4 positively affects a number of inflammatory diseases, including multiple sclerosis, or MS.

We licensed ATL1102 to Antisense Therapeutics Limited in December 2001. In 2008, ATL reported Phase 2a results of ATL1102 showing significantly reduced disease activity in patients with relapsing remitting MS.